1. Stocks
    2. /
  2. Kazia Therapeutics Ltd (ASX: KZA)
    3. /

Kazia Therapeutics Ltd (ASX: KZA) Share Price and News

Price

 

Movement

   

  (20 mins delayed)

52 Week Range

  -  

 
1 Year Return

 

Kazia Therapeutics Ltd Chart and Price Data

Fundamentals Data provided by Morningstar.

Data provided by Morningstar.
Market Cap $165.27 million
P/E Ratio N/A
Dividend Yield N/A
Shares Outstanding 129.62 million
Earnings per share -0.140
Dividend per share N/A
Year To Date Return 12.07%
Earnings Yield N/A
Franking N/A
Share Price

Day Change

52 Week Range

-

Yesterday's Close

Today's Open

Days Range

-

Volume

Avg. Volume (1 month)

Turnover

as at 24 Feb 3:44pm

Should you invest $1,000 in right now?

Before you consider , you’ll want to hear this.

Motley Fool Investing expert Scott Phillips just revealed what he believes are the 5 best stocks for investors to buy right now… and wasn’t one of them.

The online investing service he’s run for nearly a decade, Motley Fool Share Advisor, has provided thousands of paying members with stock picks that have doubled, tripled or even more.* And right now, Scott thinks there are 5 stocks that are better buys.

See The 5 Stocks

*Returns as of May 24th 2021

Kazia Therapeutics Ltd (ASX: KZA)
Latest News

KZA ASX Announcements

An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.

DateAnnouncementPrice Sensitive?TimeNo. of PagesFile Size
YesNo

About Kazia Therapeutics Ltd

Formerly Norvet Limited (NRT), 30/04/1997 ; Novogen Limited (NRT), 28/11/2017

KZA Share Price History Data provided by Morningstar.

Data provided by Morningstar.
Date Close Change % Change Volume Open High Low
27 Jul 2021 $1.29 $-0.02 -1.54% 18,360 $1.34 $1.34 $1.26
26 Jul 2021 $1.30 $-0.02 -1.52% 34,416 $1.34 $1.34 $1.25
23 Jul 2021 $1.32 $0.02 1.54% 26,414 $1.30 $1.32 $1.29
22 Jul 2021 $1.30 $0.05 4.00% 17,312 $1.27 $1.30 $1.25
21 Jul 2021 $1.25 $0.01 0.81% 68,059 $1.26 $1.26 $1.24
20 Jul 2021 $1.24 $-0.03 -2.36% 58,524 $1.26 $1.28 $1.23
19 Jul 2021 $1.27 $-0.03 -2.30% 61,030 $1.33 $1.35 $1.26
16 Jul 2021 $1.31 $0.02 1.56% 11,559 $1.30 $1.31 $1.30
15 Jul 2021 $1.28 $-0.02 -1.54% 128,209 $1.31 $1.31 $1.25
14 Jul 2021 $1.30 $0.01 0.78% 41,593 $1.30 $1.31 $1.30
13 Jul 2021 $1.29 $0.00 0.00% 19,569 $1.33 $1.33 $1.29
12 Jul 2021 $1.29 $-0.04 -3.01% 78,715 $1.33 $1.34 $1.29
09 Jul 2021 $1.33 $-0.01 -0.75% 29,182 $1.34 $1.36 $1.32
08 Jul 2021 $1.34 $0.04 3.07% 48,142 $1.37 $1.37 $1.32
07 Jul 2021 $1.31 $-0.04 -2.97% 41,222 $1.34 $1.34 $1.31
06 Jul 2021 $1.35 $-0.03 -2.18% 47,605 $1.35 $1.36 $1.32
05 Jul 2021 $1.38 $0.05 3.79% 54,927 $1.32 $1.38 $1.32
02 Jul 2021 $1.32 $0.00 0.00% 18,136 $1.30 $1.32 $1.29
01 Jul 2021 $1.32 $0.01 0.76% 41,231 $1.31 $1.32 $1.29
30 Jun 2021 $1.31 $0.03 2.34% 15,772 $1.31 $1.31 $1.30
29 Jun 2021 $1.28 $-0.02 -1.53% 53,164 $1.29 $1.30 $1.27

Director Transactions Data provided by Morningstar.

Data provided by Morningstar.
Date Director Type Amount Value Notes
02 Jun 2021 Steven Coffey Buy 8 $9,968
On-market trade.
31 May 2021 Bryce Carmine Buy 20 $24,700
On-market trade.
31 May 2021 James Garner Buy 10 $12,430
On-market trade. Avg Price.
03 May 2021 James Garner Buy 20 $27,880
On-market trade. Avg price.
03 May 2021 Steven Coffey Buy 7 $10,150
On-market trade.
30 Apr 2021 Iain Ross Buy 25 $34,925
On-market trade.
17 Dec 2020 Steven Coffey Buy 8 $10,540
On-market trade.
17 Dec 2020 Steven Coffey Buy 8 $9,818
On-market trade.
16 Dec 2020 Iain Ross Buy 30 $37,200
On-market trade. Avg price.
11 Dec 2020 James Garner Buy 37 $52,950
On-market trade. Avg price.
09 Nov 2020 James Garner Issued 800 $716,000
Employee Share Ownership Plan.
09 Nov 2020 Iain Ross Issued 400 $358,000
Employee Share Ownership Plan.
09 Nov 2020 Bryce Carmine Issued 400 $358,000
Employee Share Ownership Plan.
09 Nov 2020 Steven Coffey Issued 400 $358,000
Employee Share Ownership Plan.
12 Oct 2020 Steven Coffey Issued 62 $50,000
Rights issue.
12 Oct 2020 Bryce Carmine Issued 62 $50,000
Rights issue.
12 Oct 2020 Iain Ross Issued 125 $100,000
Rights issue.
12 Oct 2020 James Garner Issued 62 $50,000
Rights issue.
31 Aug 2020 Steven Coffey Expiry 5 $6,433
Options expired. As per announcement on 31/08/2020.
31 Aug 2020 Steven Coffey Buy 13 $14,432
On-market trade.
28 Aug 2020 Bryce Carmine Buy 23 $303,250
On-market trade.
27 Aug 2020 Iain Ross Buy 20 $20,120
On-market trade.
27 Aug 2020 James Garner Buy 25 $25,450
On-market trade.

Directors & Management Data provided by Morningstar.

Data provided by Morningstar.
Name Title Start Date Profile
Mr Steven Roy Stent Coffey Non-Executive Director Nov 2012
Mr Coffey has over 35 years of experience in the accounting and finance industry. He has been a partner in Watkins Coffey Martin since 1993. Steven sits on the board of a number of large private family companies and audits a number of large private companies and not-for-profit entities. He is Chair of Risk and Governance Committee.
Mr Iain Ross Non-Executive DirectorNon-Executive Chairman Jul 2015
Mr Ross is an experienced Director and has served on a number of Australian company boards. He is Chairman of Redx Pharma plc (LSE:REDX), Silence Therapeutics plc (LON:SLN) and Biomer Technology Limited. In his career he has held senior positions in Sandoz AG, Fisons Plc, Hoffmann-La Roche AG and Celltech Group Plc and also undertaken a number of start-ups and turnarounds on behalf of banks and private equity groups. He has over 20 years in cross-border management as a Chairman and CEO. He has led and participated in six London Stock Exchange (LSE) Initial Public Offerings (4 LSE, 1 ASX, 1 NASDAQ) and has direct experience of mergers and acquisitions transactions in Europe, USA and the Pacific Rim. His directorship includes Redx Pharma plc (LSE:REDX), Silence Therapeutics plc (LON:SLN). He is Member of Risk and Governance Committee.
Mr Bryce Carmine Non-Executive Director Jun 2015
Mr Carmine spent 36 years working for Eli Lilly & Co. and retired as Executive Vice President for Eli Lilly & Co, and President, Lilly Bio-Medicines. Prior to this he lead the Global Pharmaceutical Sales and Marketing and was a member of the company's Executive Committee. Mr Carmine previously held a series of product development portfolio leadership roles when he was named President, Global Pharmaceutical Product Development, with responsibility for the entire late-phase pipeline development across all therapeutic areas for Eli Lilly. During his career with Lilly, Bryce held several country leadership positions including President Eli Lilly Japan, Managing Dir. Australia/NZ & General Manager of a JV for Lilly in Seoul, Korea. Bryce is currently Chairman and CEO of HaemaLogiX Pty Ltd. He is Member of Risk and Governance Committee.
Dr James Garner Chief Executive OfficerManaging Director Feb 2016
Dr Garner is an experienced life sciences executive who has previously worked with companies ranging from small biotechs to multinational pharmaceutical companies such as Biogen and Takeda. His career has been on regional and global development of new medicines from preclinical to commercialisation. He began his career in hospital medicine and worked for a number of years as a corporate strategy consultant with Bain & Company before entering the pharmaceutical industry. Prior to joining Kazia in 2016, he led R&D strategy for Sanofi in Asia-Pacific and was based in Singapore.
Ms Catherine (Kate) Jane Hill Company Secretary Sep 2016
-
Catherine (Kate) Jane Hill Company Secretary
-
Gabrielle Heaton Director - Finance and Administration
-

Top Shareholders Data provided by Morningstar.

Data provided by Morningstar.
Name Shares Capital
HSBC Custody Nominees (Australia) Limited 39,899,895 42.18%
Willoughby Capital Pty Ltd 12,355,000 13.06%
Mna Family Holdings Pty Ltd 2,145,000 2.27%
Hishenk Pty Ltd 1,930,000 2.04%
BNP Paribas Noms Pty Ltd 1,687,141 1.78%
Jamplat Pty Ltd 970,000 1.03%
Citicorp Nominees Pty Umited 955,390 1.01%
Mr Iain Ross 800,001 0.85%
Comsec Nominees Pty Limited 589,104 0.62%
D& G Brown Investments Pty Limited 572,356 0.61%
Invia Custodian Pty Umited 544,354 0.58%
National Nominees Limited 505,194 0.53%
Mr Tony Mark Eldridge & Mrs Anita Maree Eldridge 505,000 0.53%
Bond Street Custodians Umited 500,000 0.53%
C & L Jackson Investments Pty Ltd 458,840 0.49%
El Coronado Holdings 453,164 0.48%
Mrs Janet Louise Bowtell & Mr Gary Owen Bowtell 360,000 0.38%
Mr Ross Richard Eddison 345,725 0.37%
CS Fourth Nominees Pty Limited 342,135 0.36%
Mrs Alison Louise Suters & Mr Mark Gerard Suters 340,076 0.36%

Profile

since

Note